Episode Thumbnail
Episode 53  |  37:22 min

Common Mistakes That Can Tank Your FDA 510(k) Submission

Episode 53  |  37:22 min  |  11.07.2019

Common Mistakes That Can Tank Your FDA 510(k) Submission

00:00
00:00
This is a podcast episode titled, Common Mistakes That Can Tank Your FDA 510(k) Submission. The summary for this episode is: Do you know the percentage of 510(k)s that are rejected by the FDA the first time? Shockingly, it’s 75%. The vast majority are rejected for poor substantial equivalence, which, as you know, defeats the purpose of the submission in the first place. Today we’re going to talk to Mike Drues, president of Vascular Sciences and regulatory guru, about some common mistakes that can sink your 510(k) submission. Some of the highlights of the show include: ● Jon’s motivation for writing an article about common mistakes that sink a 510(k) clearance. ● The importance of consistency with documentation and using the checklist off of the Refuse to Accept Policy. ● Why the Refuse to Accept guidance contains some minutiae. ● Recommendations on providing the required testing and following the best practices. ● Suggestions on how to handle showing a long shelf life. ● Thoughts on why the FDA is reluctant to accept promissory notes when a submission is not complete. ● Thoughts on risk management and why it’s an important part of a submission. ● The most important takeaways regarding the 510(k) rejection problem.
Do you know the percentage of 510(k)s that are rejected by the FDA the first time? Shockingly, it’s 75%. The vast majority are rejected for poor substantial equivalence, which, as you know, defeats the purpose of the submission in the first place. Today we’re going to talk to Mike Drues, president of Vascular Sciences and regulatory guru, about some common mistakes that can sink your 510(k) submission. Some of the highlights of the show include: ● Jon’s motivation for writing an article about common mistakes that sink a 510(k) clearance. ● The importance of consistency with documentation and using the checklist off of the Refuse to Accept Policy. ● Why the Refuse to Accept guidance contains some minutiae. ● Recommendations on providing the required testing and following the best practices. ● Suggestions on how to handle showing a long shelf life. ● Thoughts on why the FDA is reluctant to accept promissory notes when a submission is not complete. ● Thoughts on risk management and why it’s an important part of a submission. ● The most important takeaways regarding the 510(k) rejection problem.

More Episodes

Understanding and Handling Different Types of Feedback

Measuring the Impact of AI/ML Technologies on the Current Medical Device Landscape

Post-Pandemic Readiness: Preparing for the Aftermath of COVID-19 on the Medical Device Industry

Tips to Prepare for EU MDR and IVDR as Deadlines Draw Near

How will Emergency Use Authorization (EUA) during Pandemic Influence Future FDA Policy Changes?

Why SaMD Companies Should be Leveraging Pre-Submissions to FDA